Principal Financial Group Inc. Sells 11,043 Shares of Hologic, Inc. (NASDAQ:HOLX)


Share on StockTwits

Principal Financial Group Inc. lessened its stake in Hologic, Inc. (NASDAQ:HOLX) by 2.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 369,005 shares of the medical equipment provider’s stock after selling 11,043 shares during the period. Principal Financial Group Inc. owned about 0.14% of Hologic worth $26,874,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HOLX. Morgan Stanley lifted its stake in shares of Hologic by 17.5% in the 3rd quarter. Morgan Stanley now owns 563,441 shares of the medical equipment provider’s stock valued at $37,452,000 after acquiring an additional 83,742 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec bought a new stake in shares of Hologic in the 3rd quarter valued at about $279,000. Public Sector Pension Investment Board lifted its stake in shares of Hologic by 25.7% in the 3rd quarter. Public Sector Pension Investment Board now owns 31,289 shares of the medical equipment provider’s stock valued at $2,080,000 after acquiring an additional 6,400 shares during the last quarter. Engineers Gate Manager LP lifted its stake in shares of Hologic by 55.8% in the 3rd quarter. Engineers Gate Manager LP now owns 30,919 shares of the medical equipment provider’s stock valued at $2,055,000 after acquiring an additional 11,069 shares during the last quarter. Finally, State of Tennessee Treasury Department lifted its stake in shares of Hologic by 19.4% in the 3rd quarter. State of Tennessee Treasury Department now owns 295,615 shares of the medical equipment provider’s stock valued at $19,649,000 after acquiring an additional 48,111 shares during the last quarter. 92.43% of the stock is owned by institutional investors.

Hologic stock opened at $72.90 on Thursday. The company has a quick ratio of 1.47, a current ratio of 1.79 and a debt-to-equity ratio of 1.01. The company has a market capitalization of $18.78 billion, a P/E ratio of 17.36, a PEG ratio of 0.62 and a beta of 1.27. The stock’s 50 day moving average is $73.49 and its 200 day moving average is $72.88. Hologic, Inc. has a twelve month low of $37.26 and a twelve month high of $85.00.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, January 27th. The medical equipment provider reported $2.86 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.72. The company had revenue of $1.61 billion for the quarter, compared to the consensus estimate of $1.39 billion. Hologic had a return on equity of 45.24% and a net margin of 29.53%. The firm’s quarterly revenue was up 89.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.61 EPS. As a group, equities analysts expect that Hologic, Inc. will post 7.17 EPS for the current year.

In related news, insider Benjamin Jordan Cohn sold 8,396 shares of the company’s stock in a transaction that occurred on Thursday, February 4th. The stock was sold at an average price of $84.31, for a total value of $707,866.76. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.00% of the company’s stock.

HOLX has been the subject of a number of recent analyst reports. BTIG Research upped their price target on Hologic from $84.00 to $91.00 and gave the company a “buy” rating in a research report on Monday, February 22nd. Raymond James reaffirmed a “buy” rating on shares of Hologic in a research report on Wednesday, January 6th. Jefferies Financial Group upped their price target on Hologic from $106.00 to $110.00 and gave the company a “buy” rating in a research report on Monday. Robert W. Baird upped their price target on Hologic from $84.00 to $91.00 and gave the company a “buy” rating in a research report on Monday, March 1st. Finally, Zacks Investment Research downgraded Hologic from a “buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a report on Wednesday, March 31st. Five investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $85.19.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

See Also: What is meant by a buy rating?

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.